Intracardiac thrombus and multiple venous thromboses revealing focal segmental glomerulosclerosis.

CEN Case RepOct 26, 2026 (epub)

Mohammed Hamzaoui, Imane Machmachi, Khaoula Amar et al.

✦ AI-curated · Sources linked

Case in brief

A 51-year-old woman presented with two weeks of lower-limb edema and hematuria. Imaging showed lower-extremity deep vein thrombosis, partial left renal vein thrombosis, and a 23 × 20 mm left ventricular thrombus. Investigations found nephrotic syndrome, with a urine protein-to-creatinine ratio of 10 g/g and serum albumin of 23 g/L, alongside stage 2 acute kidney injury. ANCA and anti-PLA2R testing was negative; kidney biopsy established focal segmental glomerulosclerosis. Therapeutic anticoagulation, diuretics, and corticosteroids were followed by progressive clinical and biological improvement.

What made this case unusual

The combination of a left ventricular thrombus and multiple venous thromboses was the initial manifestation of nephrotic syndrome due to focal segmental glomerulosclerosis.

Diagnostic / clinical pearl

Multiple or unusual thrombotic events accompanied by substantial proteinuria should prompt evaluation for underlying glomerular disease, including kidney biopsy when indicated.

Source

Published in CEN Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.